Dobutamine-induced midcavitary gradients do not cause dyspnea  by King, Phillip et al.
Dobutamine-induced midcavitary gradients
do not cause dyspnea
Phillip King, BS, Greg Flaker, MD, FACC, FACP, FHRS, Richard Weachter, MD,
Anand Chockalingam, MD
From the University of Missouri Division of Cardiology, Columbia, Missouri.Introduction
Left ventricular outﬂow tract (LVOT) and midcavitary
gradients are common during dobutamine stress echocar-
diography. Some consider these gradients to be of no clinical
signiﬁcance.1 However, severe dobutamine-induced obstruc-
tion has been associated with chest pain and dyspnea,2
abnormalities in ventricular wall motion,3 and shock.4 These
associations suggest that dobutamine-induced gradients may
have a clinical signiﬁcance in some patients. Right ventric-
ular (RV) apical pacing has been reported to reduce LVOT
gradients in patients with hypertrophic cardiomyopathy5 but
is currently regarded as a class IIb indication for medicallyFigure 1 A: During infusion of dobutamine (5 mcg/kg/min) with a rate just unde
wave Doppler. B: During ventricular pacing at 100 bpm, there is complete resolu
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obstruction and with unfavorable characteristics for septal
reduction techniques. The role of RV apical pacing in
symptomatic patients with midcavitary gradients during
dobutamine infusion is less well deﬁned.Case presentation
A 78-year-old white male complained of having experi-
enced breathlessness since 2010. Because his ability
to exercise was poor, the patient underwent a dobutamine
stress echocardiogram. The ventricle was normal in size, with anr 1-bpm, a mid left ventricular gradient4100mm Hg is noted by continuous
tion of the midventricular gradient.estimated left ventricular ejection fraction of 60%. Mild concen-
tric hypertrophy was noted, with impaired relaxation based on
mitral inﬂow pattern. As there was no left atrial dilation, this
observation was attributed to age. Findings of hypertrophic
cardiomyopathy including focal septal hypertrophy and mitral
systolic anterior motion (SAM) were not observed. An infusion
of 50 μg/kg/min of dobutamine resulted in a blood pressure of
167mmHg and a peak heart rate of 92 beats per minute. Nowall
motion abnormalities were noted. A delayed peaking Dopplerpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.10.010
KEY TEACHING POINTS
 Right ventricular apical pacing is currently
regarded as a class IIb indication for hypertrophic
cardiomyopathy for medically refractory patients
with symptoms clearly attributed to obstruction
and with unfavorable characteristics for the
application of septal reduction techniques.
 Right ventricular apical pacing can eliminate severe
midcavitary obstruction induced during
dobutamine stress echocardiography.
 Elimination of severe midcavitary obstruction with
right ventricular apical pacing, however, may not
improve symptoms of dyspnea, and this therapy
cannot be routinely recommended for patients with
this symptom.
75King et al Midcavitary Gradients and Dyspneagradient of 180 mm Hg was observed without mitral SAM,
which was consistent with transient midcavitary obstruction. The
patient was treated with low doses of beta blockers and told to
avoid volume depletion. Symptoms persisted. Results of a chest
radiograph and pulmonary function tests were normal. The
concentration of N-terminal pro-brain natriuretic peptide was
50.6 pg/mL. Coronary angiography was performed, with no
lesion requiring intervention. An 18 mmHg aortic valve gradient
was recorded. Pulmonary pressures were not measured, because
of the absence of signiﬁcant tricuspid regurgitation; however,
there was no indirect evidence for pulmonary hypertension. The
patient walked 336 meters in 6 minutes.The patient underwent a temporary dual pacemaker
implantation. At rest, there was no midcavitary obstruction.
During dobutamine infusion of 5 μg/kg/min, a 118 mm Hg
dynamic gradient was recorded (Figure 1A). In the supine
position, the patient was without symptoms. Atrioventric-
ular pacing at 100 beats per minute immediately and
completely abolished this gradient (Figure 1B). A perma-
nent pacemaker was implanted, with the RV lead in the
apex. After 2 weeks of follow-up, during which 100%
ventricular pacing occurred, the patient continued to
complain of dyspnea. He walked 371 m in 6 minutes.
Currently, the device is programmed to minimize ventric-
ular pacing.
This case suggests that dobutamine-induced midcavitary
obstruction does not cause dyspnea.References
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